Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 plus oxaliplatin/5-FU/leucovorin vs nab-paclitaxel plus gemcitabine in first-line treatment of metastatic pancreatic cancer (phase III)
CTR20230492Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by Hengrui Therapeutics. Started Jun 2023; status: active.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20230492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230492.